SCHEMBL26918366

SCHEMBL26918366

CC(=O)c1cc(Cl)nc(C2CC2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.36
CA5A P35218 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
TAS1R2 Q8TE23 1/20 0.35
CYP17A1 P05093 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
KDM4E B2RXH2 1/20 0.33
KMT2A Q03164 1/20 0.33
PROKR1 Q8TCW9 1/20 0.33
GAA P10253 1/20 0.33
PDE4D Q08499 2/20 0.33
TYK2 P29597 1/20 0.33
AHR P35869 1/20 0.33
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TMIGD3 P0DMS9 1/20 0.32
ADORA1 P30542 1/20 0.32
S1PR2 O95136 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20186726 0.82 ALDH1A1 (0.45) POLBTAS1R3TAS1R1TAS1R2TDP1
SCHEMBL30414393 0.82 KDM5A (0.39) POLBTAS1R3TAS1R1TAS1R2CYP17A1
SCHEMBL31015715 0.81 CNR1 (0.38) POLBCYP17A1TDP1PROKR1PDE4D
SCHEMBL21743152 0.81 NPC1 (0.39) POLBCA5AKDM4EKMT2APROKR1
SCHEMBL362611 0.79 CA5A (0.48) CA5ATDP1KMT2AAHRALDH1A1
SCHEMBL26918999 0.78 ALOX15 (0.46) POLBCA5ATDP1KDM4EKMT2A
SCHEMBL15535695 0.78 KMO (0.44) POLBTAS1R3TAS1R1TAS1R2TDP1
SCHEMBL23683916 0.77 KMO (0.46) POLBTAS1R3TAS1R1TAS1R2TDP1
SCHEMBL15535176 0.76 TDP1 (0.47) POLBTAS1R3TAS1R1TAS1R2TDP1
SCHEMBL29998471 0.74 POLB (0.38) POLBKDM4EGAAPDE4DALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240300927-A1 AMIDES AS CBL-B INHIBITORS GENENTECH, INC. (US) 2024-09-12 US disclosed
EP-4288428-A1 AMIDES AS CBL-B INHIBITORS Genentech, Inc. (US) 2023-12-13 EP disclosed
WO-2022169998-A1 AMIDES AS CBL-B INHIBITORS GENENTECH, INC. (US) 2022-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300927-A1 AMIDES AS CBL-B INHIBITORS CBLB, CBL, CBLC POLB 1704/4885CA5A 4597/4885TAS1R3 4101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.